Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients

Immunotherapy

Volumn 3, Issue 6, 2011, Pages 731-733

  Hardwick, Nicola ^a   Chain, Benjamin ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cancer immunotherapy; epitope spreading; MAGE; melanoma

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 1; MELANOMA ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DNA LIBRARY; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; MELANOMA; METASTASIS; PRIORITY JOURNAL; TUMOR IMMUNITY;

EID: 79959196566     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.62     Document Type: Article

References (11)

1. Weber J: Immunotherapy for melanoma. Curr. Opin. Oncol. 23(2), 163-169 (2011).
2. Corbiere V, Chapiro J, Stroobant V et al.: Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 71(94) 1253-1262 (2011).
3. van der Bruggen P, Traversari C, Chomez P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038), 1643-1647 (1991). (Pubitemid 21917508)
4. Sang M, Wang L, Ding C et al.: Melanomaassociated antigen genes - an update. Cancer Lett. 302(2), 85-90 (2011).
5. Coulie PG, Karanikas V, Colau D et al.: A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl Acad. Sci. USA 98(18), 10290-10295 (2001). (Pubitemid 32803013)
6. Sercarz EE: Driver clones and determinant spreading. J. Autoimmun. 14(4), 275-277 (2000).
7. Drakesmith H, O'Neil D, Schneider SC et al.: In vivo priming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen. Proc. Natl Acad. Sci. USA 95(25), 14903-14908 (1998). (Pubitemid 29003729)
8. Ribas A, Timmerman JM, Butterfield LH, Economou JS: Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. 24(2), 58-61 (2003). (Pubitemid 36120639)
9. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96(9), 3102-3108 (2000).
10. Kantoff PW, Higano CS, Shore ND et al.: Sipuleucel-T immunotherapy for castrationresistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
11. Vanderlugt CL, Miller SD: Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2(2), 85-95 (2002). (Pubitemid 37323232)